Beacon Therapeutics reports positive 12-month data for XLRP gene therapy

May 7, 2026 3:00 PM

Beacon Therapeutics Holdings Limited announced 12-month safety and efficacy data from its Phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found